Key Details
Price
$1.09Annual ROE
314.14%Beta
-12.47Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
N/ARecent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in future commercialization efforts Raanana, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd.
Raanana, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the publication of a national phase patent application by the United States Patent and Trademark Office (“USPTO”). The patent application encompasses key aspects of Polyrizon's two core platform technologies: Capture and Contain (C&C™), a nasal blocker technology, and Trap and Target (T&T™), designed for advanced nasal drug delivery. Both technologies represent Polyrizon's commitment to creating innovative solutions for protecting and treating via the nasal cavity.
The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production capabilities, to support Polyrizon in future commercialization efforts
Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins' Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). This strategic appointment reflects Polyrizon's ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions.
FAQ
- What is the ticker symbol for Polyrizon?
- Does Polyrizon pay dividends?
- What sector is Polyrizon in?
- What industry is Polyrizon in?
- What country is Polyrizon based in?
- When did Polyrizon go public?
- Is Polyrizon in the S&P 500?
- Is Polyrizon in the NASDAQ 100?
- Is Polyrizon in the Dow Jones?
- When does Polyrizon report earnings?